Posted by Michael Wonder on 13 Jul 2024
Innorna announces US FDA rare paediatric disease designation granted to IN016 for the treatment of progressive familial intrahepatic cholestasis
11 July 2024 - Innorna today announced that the US FDA has granted rare paediatric disease designation to IN016, one of the Company’s lead mRNA product candidates for rare diseases.
IN016 is to treat the progressive familial intrahepatic cholestasis, a group of rare genetic disorders that cause a progressive liver disease and can lead to cirrhosis and end stage liver disease in infants and children.
